Drug intelligence / Profile preview

denosumab + etanercept

Development stage: Unknown
Lead developer: Amgen
Modality: Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Subcutaneous

Overview

A combination therapy consisting of denosumab, a fully human monoclonal antibody that targets RANKL to inhibit bone resorption, and etanercept, a TNF inhibitor used to treat inflammatory conditions. This dual biologic therapy is used primarily in patients with rheumatoid arthritis and other inflammatory rheumatic diseases who also have osteoporosis or are at risk for bone loss.

Targets

LTA (Lymphotoxin-alpha)TNFA (Tumor necrosis factor alpha (soluble))

Beyond the preview

Go deeper on denosumab + etanercept.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on denosumab + etanercept.

Explore the full profile